Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:38:00.360Z.
Calculation as of: 2026-10-06T16:38:00.360Z.
Quote observation: 2026-10-06T16:35:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85bde4aa0a662304b106d2bd805683c4a4a85ed0eecab472c1d88190f6ac555e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-08-12.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.44B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.43B
EV/FCF Ratio
86.92x
TTM Avg
263.63x
3Y Avg
263.63x
5Y Avg
163.80x
Market Cap
$1.46B
EV/FCF Ratio
8.71x
TTM Avg
9.15x
3Y Avg
21.82x
5Y Avg
100.71x
Market Cap
$1.41B
EV/FCF Ratio
72.84x
TTM Avg
54.11x
3Y Avg
63.60x
5Y Avg
65.58x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.45B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.46B | 25.43x | 17.90x | 31.06x | 41.90x |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 86.92x | 263.63x | 263.63x | 163.80x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 8.71x | 9.15x | 21.82x | 100.71x |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 72.84x | 54.11x | 63.60x | 65.58x |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.48B | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2025-08-12 | 4.85x |
| 2025-08-11 | 4.68x |
| 2025-08-08 | 4.47x |
| 2025-08-07 | 4.58x |
| 2025-08-06 | 5.17x |
| 2025-08-05 | 5.34x |
| 2025-08-04 | 5.81x |
| 2025-08-01 | 5.59x |
| 2025-07-31 | 5.49x |
| 2025-07-30 | 5.97x |
| 2025-07-29 | 6.12x |
| 2025-07-28 | 6.52x |
| 2025-07-25 | 6.81x |
| 2025-07-24 | 6.58x |
| 2025-07-23 | 7.34x |
| 2025-07-22 | 6.89x |
| 2025-07-21 | 6.71x |
| 2025-07-18 | 7.43x |
| 2025-07-17 | 6.97x |
| 2025-07-16 | 6.46x |
| 2025-07-15 | 6.30x |
| 2025-07-14 | 6.12x |
| 2025-07-11 | 5.68x |
| 2025-07-10 | 6.06x |
| 2025-07-09 | 5.70x |
| 2025-07-08 | 5.69x |
| 2025-07-07 | 3.82x |
| 2025-07-03 | 3.42x |
| 2025-07-02 | 3.65x |
| 2025-07-01 | 3.52x |
| 2025-06-30 | 3.91x |
| 2025-06-27 | 3.82x |
| 2025-06-26 | 4.21x |
| 2025-06-25 | 3.36x |
| 2025-06-24 | 2.68x |
| 2025-06-23 | 2.93x |
| 2025-06-20 | 3.22x |
| 2025-06-18 | 3.27x |
| 2025-06-17 | 3.99x |
| 2025-06-16 | 4.58x |
| 2025-06-13 | 4.63x |
| 2025-06-12 | 4.73x |
| 2025-06-11 | 4.24x |
| 2025-06-10 | 4.30x |
| 2025-06-09 | 4.26x |
| 2025-06-06 | 4.33x |
| 2025-06-05 | 4.59x |
| 2025-06-04 | 4.93x |
| 2025-06-03 | 4.80x |
| 2025-06-02 | 3.80x |
| 2025-05-30 | 2.47x |
| 2025-05-29 | 3.85x |
| 2025-05-28 | 3.41x |
| 2025-05-27 | 3.23x |
| 2025-05-23 | 2.64x |
| 2025-05-22 | 2.57x |
| 2025-05-21 | 2.80x |
| 2025-05-20 | 2.54x |
| 2025-05-19 | 2.27x |
| 2025-05-16 | 1.99x |
| 2025-05-15 | 1.99x |
| 2025-05-14 | 3.03x |
| 2025-05-13 | 3.50x |
| 2025-05-12 | 3.66x |
| 2025-05-09 | 3.36x |
| 2025-05-08 | 3.59x |
| 2025-05-07 | 3.28x |
| 2025-05-06 | 3.06x |
| 2025-05-05 | 3.83x |
| 2025-05-02 | 4.08x |
| 2025-05-01 | 3.92x |
| 2025-04-30 | 3.14x |
| 2025-04-29 | 2.87x |
| 2025-04-28 | 2.63x |
| 2025-04-25 | 2.53x |
| 2025-04-24 | 2.23x |
| 2025-04-23 | 3.32x |
| 2025-04-22 | 3.50x |
| 2025-04-21 | 3.07x |
| 2025-04-17 | 2.65x |
| 2025-04-16 | 2.51x |
| 2025-04-15 | 2.47x |
| 2025-04-14 | 2.70x |
| 2025-04-11 | 2.31x |
| 2025-04-10 | 2.17x |
| 2025-04-09 | 2.39x |
| 2025-04-08 | 2.16x |
| 2025-04-07 | 2.95x |
| 2025-04-04 | 3.04x |
| 2025-04-03 | 3.18x |
| 2025-04-02 | 3.80x |
| 2025-04-01 | 3.52x |
| 2025-03-31 | 5.33x |
| 2025-03-28 | 5.56x |
| 2025-03-27 | 5.48x |
| 2025-03-26 | 5.19x |
| 2025-03-25 | 5.68x |
| 2025-03-24 | 5.81x |
| 2025-03-21 | 5.41x |
| 2025-03-20 | 5.87x |
| 2025-03-19 | 5.97x |
| 2025-03-18 | 5.93x |
| 2025-03-17 | 5.60x |
| 2025-03-14 | 5.32x |
| 2025-03-13 | 5.50x |
| 2025-03-12 | 5.50x |
| 2025-03-11 | 5.45x |
| 2025-03-10 | 5.77x |
| 2025-03-07 | 5.89x |
| 2025-03-06 | 5.74x |
| 2025-03-05 | 5.82x |
| 2025-03-04 | 5.80x |
| 2025-03-03 | 5.35x |
| 2025-02-28 | 6.02x |
| 2025-02-27 | 6.30x |
| 2025-02-26 | 5.72x |
| 2025-02-25 | 5.08x |
| 2025-02-24 | 5.22x |
| 2025-02-21 | 5.94x |
| 2025-02-20 | 5.99x |
| 2025-02-19 | 6.21x |
| 2025-02-18 | 6.34x |
| 2025-02-14 | 5.89x |
| 2025-02-13 | 5.51x |
| 2025-02-12 | 5.88x |
| 2025-02-11 | 6.16x |
| 2025-02-10 | 6.44x |
| 2025-02-07 | 6.68x |
| 2025-02-06 | 6.46x |
| 2025-02-05 | 6.36x |
| 2025-02-04 | 6.60x |
| 2025-02-03 | 7.59x |
| 2025-01-31 | 8.13x |
